Aptevo Therapeutics Inc., of Seattle, commenced patient dosing in a phase II clinical evaluation of otlertuzumab in a new indication – peripheral T-cell lymphoma (PTCL). Otlertuzumab is a monospecific antibody targeting CD37 that was built on Aptevo’s Adaptir modular protein therapeutic platform.